Get the Stockscreener App
49.97
2.02%
-1.03
After Hours:
49.00
-0.97
-1.94%
Biohaven Ltd stock is traded at $49.97, with a volume of 914.55K.
It is down -2.02% in the last 24 hours and up +26.83% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$51.00
Open:
$50.44
24h Volume:
914.55K
Relative Volume:
0.94
Market Cap:
$4.77B
Revenue:
-
Net Income/Loss:
$-746.61M
P/E Ratio:
-6.6894
EPS:
-7.47
Net Cash Flow:
$-485.24M
1W Performance:
+8.77%
1M Performance:
+26.83%
6M Performance:
-8.63%
1Y Performance:
+92.12%
1-Day Range:
$49.67
$51.34
1-Week Range:
$43.84
$51.99
52-Week Range:
$22.12
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust By Investing.com - Investing.com South Africa
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust - Investing.com India
Biohaven launches $250 million public stock offering - Investing.com
Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire
Biohaven starts phase 2 trial for new migraine treatment - Investing.com
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - Nasdaq
Driehaus Capital Management LLC Lowers Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday - MSN
Cubist Systematic Strategies LLC Invests $3.40 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Fred Alger Management LLC Has $1.40 Million Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Wall Street SWOT: Biohaven stock rides wave of promising pipeline developments - Investing.com
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - MSN
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Yahoo Finance
Leerink Partnrs Weighs in on Biohaven Ltd.'s Q3 2024 Earnings (NYSE:BHVN) - MarketBeat
Armistice Capital LLC Acquires 597,705 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Biohaven (NYSE:BHVN) Stock Price Up 7.4% After Insider Buying Activity - MarketBeat
Director Gregory Bailey Acquires 5,000 Shares of Biohaven Ltd (B - GuruFocus.com
Gregory Bailey Purchases 5,000 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - MarketBeat
Biohaven director Bailey Gregory buys $221k worth of shares By Investing.com - Investing.com South Africa
Biohaven director Bailey Gregory buys $221k worth of shares By Investing.com - Investing.com Australia
Biohaven director Bailey Gregory buys $221k worth of shares - Investing.com India
Biohaven director Bailey Gregory buys $221k worth of shares - Investing.com
Biohaven director Bailey Gregory buys $221k worth of shares By Investing.com - Investing.com UK
Sanford C. Bernstein Boosts Biohaven (NYSE:BHVN) Price Target to $66.00 - Defense World
Biohaven (NYSE:BHVN) Price Target Raised to $62.00 - Defense World
why Biohaven Ltd [BHVN] is a Good Choice for Investors After New Price Target of $60.36 - The DBT News
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Benzinga
Leerink lifts Biohaven stock target, holds rating on SCA drug potential - Investing.com India
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Zacks Investment Research
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Yahoo Finance
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MarketBeat
Biohaven Ltd (BHVN-N) QuotePress Release - The Globe and Mail
Biohaven’s real-world trial shows positive results for spinocerebellar ataxia drug - OutSourcing-Pharma.com
Biohaven (NYSE:BHVN) Rating Reiterated by Cantor Fitzgerald - Defense World
Biohaven (NYSE:BHVN) Price Target Increased to $66.00 by Analysts at Sanford C. Bernstein - MarketBeat
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia - BioSpace
Biohaven (NYSE:BHVN) Rating Reiterated by Cantor Fitzgerald - MarketBeat
Biohaven price target raised to $68 from $59 at RBC Capital - TipRanks
Magnetar Financial LLC Invests $2.06 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Scores Relative Strength Rating Upgrade - Investor's Business Daily
BayWa jumps after first draft of restructuring plan - XM
Biohaven Returns With Positive RWE Data In Spinocerebellar Ataxia - Scrip
Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With No Approved Meds - MedCity News
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease - Investor's Business Daily
Stock Analysts’ Price Target Changes for September 23rd (AGF.B, AP.UN, ARE, BDTX, BHVN, BLCO, BTO, D.UN, KEY, OSK) - Defense World
Troriluzole shows promise in slowing SCA progression - Investing.com India
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst (NYSE:BHVN) - Seeking Alpha
Biohaven’s stock surges as treatment slows progress of neurological disorder - MSN
Biohaven shares target raised on new data optimism - Investing.com India
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):